Patents by Inventor Seok Ho Yoo
Seok Ho Yoo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Anode active material for lithium secondary battery and lithium secondary battery including the same
Patent number: 11967705Abstract: An anode active material for a lithium secondary battery includes a carbon-based particle including pores therein, a silicon-containing coating layer formed at an inside the pores of the carbon-based particle or on a surface of the carbon-based particle, and a carbon coating layer formed on the silicon-containing coating layer. A full width at half maximum (FWHM) of an O1s peak of a surface measured by an X-ray photoelectron spectroscopy (XPS) is 2.0 or more. A lithium secondary battery including the anode active material having improved initial discharge capacity and capacity efficiency is provided.Type: GrantFiled: July 1, 2022Date of Patent: April 23, 2024Assignee: SK ON CO., LTD.Inventors: Gwi Ok Park, Seok Keun Yoo, Dong Il Jang, Ju Ho Chung -
Publication number: 20240128443Abstract: A silicon-carbon containing electrode material includes a porous carbon structure including pores, and a silicon-containing coating formed on the porous carbon structure. A volume ratio of mesopores is 70% or more based on a total pore volume of the porous carbon structure. A weight ratio of silicon is 30 wt % or more based on a total weight of the electrode material. A high-capacity secondary battery is effectively implemented by using silicon-carbon containing electrode material.Type: ApplicationFiled: September 21, 2023Publication date: April 18, 2024Inventors: Hee Soo KIM, Yeon Ho KIM, Young Kwang KIM, Young Eun CHEON, Gwi Ok PARK, Seok Keun YOO
-
Patent number: 11945864Abstract: A monoclonal antibody or an antigen-binding fragment thereof according to an embodiment of the present invention can bind to lymphocyte-activation gene 3 (LAG-3) including a heavy chain variable region and a light chain variable region and inhibit the activity thereof. Thus it is expected to be useful for the development of immunotherapeutic agents for various disorders that are associated with LAG-3.Type: GrantFiled: June 28, 2019Date of Patent: April 2, 2024Assignee: Y-BIOLOGICS INC.Inventors: Sang Pil Lee, Ji-Young Shin, Sunha Yoon, Yunseon Choi, Jae Eun Park, Ji Su Lee, Youngja Song, Gisun Baek, Seok Ho Yoo, Yeung-chul Kim, Dong Jung Lee, Bum-Chan Park, Young Woo Park
-
Publication number: 20240088389Abstract: An anode active material for a lithium secondary battery and a lithium secondary battery are provided. The anode active material includes a carbon-based particle including pores formed in at least one of an inside of the particle and a surface of the particle and having a pore size of the carbon-based particle is 20 nm or less, and silicon formed at an inside of the pores of the carbon-based particle or on the surface of the carbon-based particle. Silicon has an amorphous structure or a crystallite size of silicon measured by an XRD analysis is 7 nm or less. Difference between volume expansion ratios of carbon and silicon can be reduced to improve life-span property of the secondary battery.Type: ApplicationFiled: November 15, 2023Publication date: March 14, 2024Inventors: Gwi Ok PARK, Seok Keun YOO, Ju Ho CHUNG
-
Publication number: 20220348663Abstract: Provided are an anti-B7-H3 antibody binding specifically to B7-H3 and a use thereof and, more particularly, are an anti-B7-H3 antibody or an antigen binding fragment thereof, a nucleic acid encoding the same, a vector carrying the nucleic acid, a cell transformed with the vector, a method for preparing the same, an antibody-drug conjugate or a multi-specific antibody comprising the same, and a pharmaceutical composition for preventing or treating cancer, autoimmune disease, or inflammatory disease, or a diagnostic composition, each composition comprising the same. The anti-B7-H3 antibody or antigen binding fragment thereof can bind to human and non-human B7-H3 at high affinity and can be endocytosized after binding thereto. Thus, the anti-B7-H3 antibody or antigen binding fragment thereof, or the antibody-drug conjugate or the multi-specific antibody comprising the same can be advantageously used for preventing, treating, or diagnosing cancer or tumor, autoimmune disease, or inflammatory disease.Type: ApplicationFiled: July 8, 2020Publication date: November 3, 2022Inventors: Hyun Ju LEE, Eun-Young SHIM, Yunjung KO, Jin-Chul YOUN, Jae Eun PARK, Soo A CHOI, Seok Ho YOO, Dong Jung LEE, Yeung-Chul KIM, Youngja SONG, Jisu LEE, Ju-Ry LIM, Bum-Chan PARK, Young Woo PARK
-
Patent number: 11306141Abstract: The present invention relates to an antibody against delta-like 1 homolog (Drosophila) (DLK1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, an antibody drug conjugate (ADC) comprising the same, a pharmaceutical composition for treating cancer, a composition for diagnosing cancer, and a chimeric antigen receptor (CAR) and a T-cell engager comprising the same.Type: GrantFiled: September 10, 2018Date of Patent: April 19, 2022Assignee: Y-BIOLOGICS INC.Inventors: Jung Chae Lim, Ji-Young Shin, Sunha Yoon, Sang Pil Lee, Yunseon Choi, Jisu Lee, Young-Gyu Cho, Seok Ho Yoo, Yeung chul Kim, Si Hyung Lee, Jae Eun Park, Youngja Song, Gi Sun Baek, Bum-chan Park, Young Woo Park
-
Publication number: 20220098297Abstract: A bispecific antibody according to an embodiment of the present disclosure specifically binds to IL-17A and TNF-?. The bispecific antibody according to the present invention or an antigen binding fragment thereof exhibits high specificity for IL-17A and TNF-? and more favorable neutralization property compared to monospecific antibody of a prior art, and, by quickly suppressing inflammation and an immune response by inhibiting simultaneously IL-17 and TNF-?, it has an advantage of improving the treatment effect with lower dose.Type: ApplicationFiled: April 20, 2020Publication date: March 31, 2022Inventors: Jae Bong YOON, Eun Young JEON, Gi Sun BAEK, Seok Ho YOO, Bum-Chan PARK, Young Woo PARK
-
Publication number: 20210238283Abstract: A monoclonal antibody or an antigen-binding fragment thereof according to an embodiment of the present invention can bind to lymphocyte-activation gene 3 (LAG-3) including a heavy chain variable region and a light chain variable region and inhibit the activity thereof. Thus it is expected to be useful for the development of immunotherapeutic agents for various disorders that are associated with LAG-3.Type: ApplicationFiled: June 28, 2019Publication date: August 5, 2021Inventors: Sang Pil LEE, Ji-Young SHIN, Sunha YOON, Yunseon CHOI, Jae Eun PARK, Ji Su LEE, Youngja SONG, Gisun BAEK, Seok Ho YOO, Yeung-chul KIM, Dong Jung LEE, Bum-Chan PARK, Young Woo PARK
-
Publication number: 20210214432Abstract: The present invention relates to an antibody against delta-like 1 homolog (Drosophila) (DLK1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, an antibody drug conjugate (ADC) comprising the same, a pharmaceutical composition for treating cancer, a composition for diagnosing cancer, and a chimeric antigen receptor (CAR) and a T-cell engager comprising the same.Type: ApplicationFiled: September 10, 2018Publication date: July 15, 2021Inventors: Jung Chae Lim, Ji-Young Shin, Sunha Yoon, Sang Pil Lee, Yunseon Choi, Jisu Lee, Young-Gyu Cho, Seok Ho Yoo, Yeung chul Kim, Si Hyung Lee, Jae Eun Park, Youngja Song, Gi Sun Baek, Bum-chan Park, Young Woo Park
-
Patent number: 10448662Abstract: The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 or a fragment thereof with a human antibody Fc region. Also provided are health functional foods containing a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 (delta-like 1 homolog) or a fragment thereof with a human antibody Fc region as an active ingredient.Type: GrantFiled: October 28, 2016Date of Patent: October 22, 2019Assignees: Y-Biologics Inc., Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Young Woo Park, Bum-chan Park, Bong-soo Cha, Yong Ho Lee, Jung Chae Lim, Young-gyu Cho, Joong Kyu Kim, Jae Eun Park, Seok Ho Yoo
-
Patent number: 10259850Abstract: Provided are a modified DKK2 polypeptide according to an aspect, a nucleic acid encoding the same, a preparation method thereof, and use thereof. Accordingly, a modified DKK2 protein having an additional glycosyl group or improved binding affinity for a substrate LRP6 may be efficiently prepared, thereby being used for promoting angiogenesis or preventing or treating vascular permeability-related diseases.Type: GrantFiled: February 3, 2016Date of Patent: April 16, 2019Assignee: MEDPACTO INC.Inventors: Il Ho Ha, Seok Ho Yoo, Hye Nan Kim, Yeung Chul Kim, Ju Ry Lim
-
Patent number: 10087248Abstract: The present invention relates to a TNF-? (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-? specific antibody, is a bispecific antibody that effectively binds to both TNF-? and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-?/CXCL10. A composition of the present invention comprises a TNF-?/CXCL-10 double targeting antibody which effectively binds to both TNF-? and CXCL10. The double targeting antibody of the present invention has excellent TNF-? inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-? or CXCL10 single targeting antibody.Type: GrantFiled: May 22, 2014Date of Patent: October 2, 2018Assignee: METABOLIC ENGINEERING LABORATORIES CO., LTD.Inventors: Heun-Soo Kang, So-Hyun Park, Yeong Wook Song, Ki Chul Shin, Eun Young Lee, Eun Bong Lee, Young Woo Park, Bum-Chan Park, Dong Hee Lee, Dong Jin Kim, Seon Ha Yun, Ke Se Lee, Hyun Ju Lee, Kyung Jin Kim, Hee Chan Kim, Seok Ho Yoo, Myeoung Hee Jang, Seil Jang
-
Publication number: 20180016313Abstract: Provided are a modified DKK2 polypeptide according to an aspect, a nucleic acid encoding the same, a preparation method thereof, and use thereof. Accordingly, a modified DKK2 protein having an additional glycosyl group or improved binding affinity for a substrate LRP6 may be efficiently prepared, thereby being used for promoting angiogenesis or preventing or treating vascular permeability-related diseases.Type: ApplicationFiled: February 3, 2016Publication date: January 18, 2018Applicant: MEDPACTO INC.Inventors: Il Ho HA, Seok Ho YOO, Hye Nan KIM, Yeung Chul KIM, Ju Ry LIM
-
Publication number: 20170121380Abstract: The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 or a fragment thereof with a human antibody Fc region. Also provided are health functional foods containing a DLK1-Fc fusion protein constructed by conjugation of an extracellular domain of DLK1 (delta-like 1 homolog) or a fragment thereof with a human antibody Fc region as an active ingredient.Type: ApplicationFiled: October 28, 2016Publication date: May 4, 2017Inventors: Young Woo Park, Bum-chan Park, Bong-soo Cha, Yong Ho Lee, Jung Chae Lim, Young-gyu Cho, Joong Kyu Kim, Jae Eun Park, Seok Ho Yoo
-
Patent number: 9631020Abstract: Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.Type: GrantFiled: June 4, 2012Date of Patent: April 25, 2017Assignees: Korea Research Institute of Bioscience and Biotechnology, Y-Biologics Inc.Inventors: Young Woo Park, Ki Won Jo, Chan Woong Park, Seok Ho Yoo, Myeoung Hee Jang, Hye Nan Kim, Seon Ha Yun, Kyu Won Cho, Mi Ra Park
-
Patent number: 9388223Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.Type: GrantFiled: January 3, 2013Date of Patent: July 12, 2016Assignee: Antibody and Receptor Therapeutics Co., Ltd.Inventors: Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
-
Patent number: 9364556Abstract: The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual.Type: GrantFiled: November 28, 2012Date of Patent: June 14, 2016Assignees: Korea Research Institute of Bioscience and Biotechnology, A&RT Co., Ltd.Inventors: Young Woo Park, Ki Won Jo, Sun Jeong Jo, Soon Sil Hyun, Jae Eun Park, Seok Ho Yoo, Myeoung Hee Jang, Hye Nan Kim, Chan Woong Park
-
Publication number: 20160108118Abstract: The present invention relates to a TNF-? (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-? specific antibody, is a bispecific antibody that effectively binds to both TNF-? and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-?/CXCL10. A composition of the present invention comprises a TNF-?/CXCL-10 double targeting antibody which effectively binds to both TNF-? and CXCL10. The double targeting antibody of the present invention has excellent TNF-? inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-? or CXCL10 single targeting antibody.Type: ApplicationFiled: May 22, 2014Publication date: April 21, 2016Applicant: METABOLIC ENGINEERING LABORATORIES CO., LTD.Inventors: Heun-Soo Kang, So-Hyun Park, Yeong Wook Song, Ki Chul Shin, Eun Young Lee, Eun Bong Lee, Young Woo Park, Bum-Chan Park, Dong Hee Lee, Dong Jin Kim, Seon Ha Yun, Ke Se Lee, Hyun Ju Lee, Kyung Jin Kim, Hee Chan Kim, Seok Ho Yoo, Myeoung Hee Jang, Seil Jang
-
Publication number: 20150110815Abstract: The present invention relates to a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody. More specifically, the present invention relates to: a drug conjugate comprising a cytotoxic drug conjugated to a c-Met specific human antibody; a pharmaceutical composition for cancer treatment comprising the drug conjugate; and a cancer treatment method comprising a step in which the drug conjugate or pharmaceutical composition is administered to an individual.Type: ApplicationFiled: November 28, 2012Publication date: April 23, 2015Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Young Woo Park, Ki Won Jo, Sun Jeong Jo, Soon Sil Hyun, Jae Eun Park, Seok Ho Yoo, Myeoung Hee Jang, Hye Nan Kim, Chan Woong Park
-
Publication number: 20150030595Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.Type: ApplicationFiled: January 3, 2013Publication date: January 29, 2015Inventors: Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim